The alcohol-intake paradox: caution in a field of developing evidence. Response

La paradoja del consumo de alcohol: cautela ante una evidencia en desarrollo. Respuesta

To the Editor,

We are writing in reference to our editorial, in which we mention that the most effective measures shown to extend life expectancy include moderate alcohol intake (5-14.9 g of ethanol/day). A healthy lifestyle, including moderate intake of alcoholic beverages, led to a reduction of 74% in all-cause death, 65% in cancer mortality, and 82% in cardiovascular mortality.

Numerous studies have found that moderate alcohol intake has a protective effect on the cardiovascular system. Meta-analysis results indicate that a moderate intake of alcoholic beverages—mainly wine—lowers the risk of breast cancer, provided that it is part of a healthy dietary pattern. These studies take into consideration the presence of confounding factors, such as the lack of “patients” in the control arm (abstainers), avoid inaccurate records on the use of alcoholic beverages, specify the alcohol intake pattern (differentiating between daily alcohol intake and cumulative weekend or binge drinking), and look at the effect of healthy dietary patterns, such as the Mediterranean diet. Additionally, in vitro studies have identified various possible mechanisms for the protective effects of moderate alcohol intake, supporting the plausibility of epidemiologic results.

In conclusion, as clinicians we have sufficient evidence to counsel patients according to alcohol consumption: a) patients who drink in excess should be urged to reduce intake to less than 20 g of alcohol a day for men and less than 10 g for women; b) patients with moderate alcohol intake should be reminded to avoid any increase in intake, and c) patients who abstain should never be advised to drink alcohol. All of these patients should be encouraged to eat a healthy diet, namely the Mediterranean diet, and those who drink alcohol should be directed to preferably drink wine or beer, always with meals.

FUNDING

The authors state that they received no funding for this manuscript.

AUTHORS’ CONTRIBUTIONS

Both authors contributed equally to this manuscript.

CONFLICTS OF INTEREST

R. Estruch states that he has received research aid from the Carlos III Health Institute, the Health Research Fund, and CIBER Physiopathology of Obesity and Nutrition and that he is a member of the Advisory Board of the Mediterranean Diet Foundation, the Beer and Health Foundation, and the Foundation for Wine and Nutrition Research (FIVIN). He has received aid from the European Union (EIT-Health) and Laboratoires Grand Fontaine, Spain, to conduct clinical trials and has given educational lectures for the Cervantes Institute (Madrid), Brewers of Europe (Belgium), Wine in Moderation (Belgium), Uriach (Barcelona), and Lilly (Madrid). He has also received travel aid from the Karolinska Institute (Sweden) and from ERAB (Belgium). Last, he is a member of the Data Safety Monitoring Board for the CARDIOPRE study (Spain). E. Scanella declares no conflicts of interest.

Ramón Estruchab,*, and Emilio Sacanellaa,b

aServicio de Medicina Interna, Hospital Clínico, IDIBAPS, Universidad de Barcelona, Barcelona, Spain
bCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Spain

* Corresponding author:
E-mail address: restruch@clinic.cat (R. Estruch).

Available online 15 October 2021

REFERENCES


https://doi.org/10.1016/j.rec.2021.08.014
1885-5857/© 2021 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

SEE RELATED CONTENT:
https://doi.org/10.1016/j.rec.2021.09.017
1885-5857/© 2021 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.